<DOC>
	<DOCNO>NCT01013415</DOCNO>
	<brief_summary>The purpose study find safety activity experimental anti-HIV treatment use autologous CD4-zeta gene-changed T cell and/or IL-2 ( recombinant interleukin2 ) . The treatment investigator study try improve immune system change T cell find destroy HIV infect cell ( HIV usually able hide T cell ) . In study , investigator also try find give IL-2 time gene change T cell help T cell live long fight HIV better .</brief_summary>
	<brief_title>CD4-ZETA Gene Modified T Cells With Without Exogenous Interleukin-2 ( IL-2 ) In HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DOD beneficiary HIV1 infection Greater equal 200 CD4 cells/mm3 Undetectable viral load , least previous 8 week Stable antiretroviral regimen great equal 8 week Venous access sufficient apheresis Karnofsky performance &gt; 80 % Inadequate organ function Lifetime history CD4 count le 200 cells/mm3 2 consecutive measurement least 8 week period Any previous history gene therapy Recent IL2 therapy treatment investigational agent Pregnancy medication ( hydroxyurea , corticosteroid immunosuppressant , chemotherapy , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Infection HIV-1 undetectable viral load HAART therapy</keyword>
</DOC>